Interviews with leading Life Sciences companies: Cellestia Biotech AG

Created by two scientists at the École
Politechnique Fédérale de Lausanne (EPFL) in 2014 and
joined by experienced drug development and business
professionals in 2015, Cellestia Biotech AG is developing
oral medication along with companion diagnostics for
Notch dependent hematological malignancies and solid tumors.
Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel, Switzerland.

Read the interview